financetom
Business
financetom
/
Business
/
SolarEdge Technologies Swings to Non-GAAP Loss in Q1, Revenue Declines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SolarEdge Technologies Swings to Non-GAAP Loss in Q1, Revenue Declines
May 9, 2024 1:18 AM

04:09 AM EDT, 05/09/2024 (MT Newswires) -- SolarEdge Technologies ( SEDG ) reported a Q1 non-GAAP loss late Wednesday of $1.90 per diluted share, swinging from earnings of $2.90 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.59.

Revenue for the quarter ended March 31 was $204.4 million, compared with $943.9 million a year earlier.

Analysts surveyed by Capital IQ expected $194.4 million.

The company said it expects Q2 revenue of $250 million to $280 million. Analysts surveyed by Capital IQ expect $305.2 million.

The company's share price was down 8.5% in premarket activity Thursday.

Price: 52.66, Change: -4.89, Percent Change: -8.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mckesson Insider Sold Shares Worth $2,155,761, According to a Recent SEC Filing
Mckesson Insider Sold Shares Worth $2,155,761, According to a Recent SEC Filing
Jun 6, 2024
04:51 PM EDT, 06/06/2024 (MT Newswires) -- Brian S. Tyler, Director, Chief Executive Officer, on June 05, 2024, sold 3,753 shares in Mckesson (MCK) for $2,155,761. Following the Form 4 filing with the SEC, Tyler has control over a total of 90,059 shares of the company, with 89,845 shares held directly and 214 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/927653/000106299324012074/xslF345X03/form4.xml ...
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold
Jun 6, 2024
04:56 PM EDT, 06/06/2024 (MT Newswires) -- Biomea Fusion ( BMEA ) said Thursday it received a notice from the US Food and Drug Administration that a full clinical hold has been placed on its phase I/II trials of its investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes. The FDA cited deficiencies based on the level...
Coherent Insider Sold Shares Worth $948,505, According to a Recent SEC Filing
Coherent Insider Sold Shares Worth $948,505, According to a Recent SEC Filing
Jun 6, 2024
04:51 PM EDT, 06/06/2024 (MT Newswires) -- Michael L Dreyer, Director, on June 05, 2024, sold 14,239 shares in Coherent (COHR) for $948,505. Following the Form 4 filing with the SEC, Dreyer has control over a total of 18,552 shares of the company, with 18,552 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/820318/000082031824000012/xslF345X03/primary_doc.xml Price: 65.98, Change: -0.14, Percent Change: -0.21 ...
FS KKR Capital Closes $600 Million Offering of Notes Due 2029
FS KKR Capital Closes $600 Million Offering of Notes Due 2029
Jun 6, 2024
04:58 PM EDT, 06/06/2024 (MT Newswires) -- FS KKR Capital ( FSK ) said Thursday it completed a $600 million public offering of 6.875% unsecured notes due 2029. Net proceeds from the offering will be used for general corporate purposes, including debt repayment, the company said. Price: 20.62, Change: +0.05, Percent Change: +0.24 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved